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Primary hyperparathyroidism associated with multiple endocrine neoplasia type I (hyperparathyroidism/multiple
endocrine neoplasia type 1) differs in many aspects from sporadic hyperparathyroidism, which is the most
frequently occurring form of hyperparathyroidism. Bone mineral density has frequently been studied in sporadic
hyperparathyroidism but it has very rarely been examined in cases of hyperparathyroidism/multiple endocrine
neoplasia type 1. Cortical bone mineral density in hyperparathyroidism/multiple endocrine neoplasia type 1 cases
has only recently been examined, and early, severe and frequent bone mineral losses have been documented at this
site. Early bone mineral losses are highly prevalent in the trabecular bone of patients with hyperparathyroidism/
multiple endocrine neoplasia type 1. In summary, bone mineral disease in multiple endocrine neoplasia type 1-
related hyperparathyroidism is an early, frequent and severe disturbance, occurring in both the cortical and
trabecular bones. In addition, renal complications secondary to sporadic hyperparathyroidism are often studied, but
very little work has been done on this issue in hyperparathyroidism/multiple endocrine neoplasia type 1. It has been
recently verified that early, frequent, and severe renal lesions occur in patients with hyperparathyroidism/multiple
endocrine neoplasia type 1, which may lead to increased morbidity and mortality. In this article we review the few
available studies on bone mineral and renal disturbances in the setting of hyperparathyroidism/multiple endocrine
neoplasia type 1. We performed a meta-analysis of the available data on bone mineral and renal disease in cases of
multiple endocrine neoplasia type 1-related hyperparathyroidism.
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INTRODUCTION
Hyperparathyroidism in multiple endocrine
neoplasia type 1
Primary hyperparathyroidism (HPT) is one of the most
common endocrine diseases, with an estimated prevalence
of 1–21 cases per 1,000 and an incidence of 27–30 cases per
100,000 person-years (1). HPT is biochemically characterized
by hypercalcemia associated with abnormally high serum
levels of parathyroid hormone (PTH). It is caused by
parathyroid adenoma in 80–90% of cases, parathyroid
hyperplasia in 10–15% of cases, and carcinoma in less than
1% of cases (2–4).
HPT occurs predominantly as a sporadic disease in 95%
of cases; the remaining 5% of cases are hereditary forms of
the disease (2–6). It is worth noting that subtotal or total
parathyroidectomy (PTx) is usually recommended for the
treatment of inherited HPT cases, whereas adenomectomy
is indicated for the vast majority of sporadic HPT cases (6–
8). As part of the familial HPT subset, HPT associated
with multiple endocrine neoplasia type 1 (HPT/MEN1)
comprises up to 4.5% of all HPT cases (9). MEN1 is a
complex autosomal-dominant hereditary disorder char-
acterized by a high predisposition to develop a wide
spectrum of endocrine and non-endocrine tumors. MEN1
is defined by the presence of tumors in at least two of the
three main endocrine glands involved in this syndrome
(i.e., the parathyroids, the pituitary gland, and the
endocrine cells of the pancreas/duodenum). Familial
MEN1 is determined by the identification of at least one
of the major tumors in a family member of the index case
with MEN1 (5). HPT is the most frequent tumor in MEN1,
reaching nearly complete penetrance by the time the
patient is 50 years of age. Sporadic HPT (S-HPT) differs
from MEN1-related HPT in many ways and the recogni-
tion of these differences may help to reveal the diagnosis
of MEN1 (Table 1) (10).
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99A marked change in the clinical picture of HPT occurred
after the widespread introduction of annual calcium
measurements using multichannel analyzers in the mid
1970s in the USA and Europe. Beyond increasing prevalence
of S-HPT, this practice resulted in crescent diagnosis of the
asymptomatic form of HPT and progressive decreasing of
symptomatic cases. Thus, renal, bone and neurological
complications secondary to S-HPT are increasingly uncom-
mon nowadays in countries where routine measurements of
serum calcium are performed (1–4).
At present, most S-HPT cases are asymptomatic and
characterized by vague neurocognitive symptoms such as
pain, fatigue, depression, and milder degrees of bone and
renal disease mainly characterized for reduced creatinine
clearance rate and bone demineralization (1–4).
Other tumors associated with MEN1
Multiple duodenal gastrinomas and non-functioning
pancreatic neuroendocrine tumors occur in 40% and 34%
of cases, respectively, at around 50 years of age. Because of
their high potential for malignancy, these types of tumors
are the major causes of MEN1-related morbidity and
mortality (5,11,12). Several tumors that may be associated
with MEN1 have a high potency for malignancy but occur at
low frequencies (2%), such as glucagonomas, somatostati-
nomas and pancreatic polypeptide or vasoactive intestinal
polypeptide secreting tumors. (5).
Pituitary tumors may occur in up to 30–40% of the
patients with MEN1, mostly in the form of prolactinomas
and non-functioning and co-secreting pituitary adenomas.
In addition, corticotrophin-secreting tumors may potentially
lead to Cushing’s disease. It should also be noted that
acromegaly/gigantism is less prevalent in MEN1, and other
forms of familial acromegaly should be ruled out (13–19).
A wide spectrum of other endocrine tumors may be present,
such as thymic, bronchial and gastric carcinoids and non-
functioning adrenocortical tumors, as well as non-endocrine
tumors, such as facial angiofibromas, collagenomas, lipomas,
meningeomas, ependimomas, and pinealomas (5,20,21).
Genetic aspects
The gene responsible for MEN1 syndrome, MEN1 gene,
is localized to chromosome 11q13 and belongs to a class of
tumor suppressor genes. The MEN1 gene codes Menin, a
ubiquitously expressed nuclear protein that interacts
directly with proteins involved in transcriptional regula-
tion, genome stability, cell division, and cell cycle control
(20). More than 1,000 mutations of the MEN1 gene
associated with MEN1 syndrome have been described to
date (22). Also, in case series, new germline MEN1
mutations were documented by our group and all types
of mutations have been observed, mostly those leading to
the truncation of the Menin protein (23,24). Point muta-
tions in the MEN1 gene represent up to 20% of cases, as
recently confirmed by us (www.arup.utah.edu/database/
men1/classification.php). Furthermore, Menin interacts
with several partners (25–28).
OBJECTIVE
Very few papers have addressed the bone mineral and
renal complications that occur secondary to MEN1-related
HPT, the shift to the asymptomatic form, and the natural
history of this disorder. In this review, we present a meta-
analysis of the current literature on this subject.
Biochemical, bone mineral and renal disease in HPT
related to MEN1
Burgess series. The first study on bone mineral status in
MEN1 was published by Burgess et al. in 1998 (29). In this
paper, 29 women with HPT from a large Tasmanian family
with MEN1 were studied. Bone mineral density (BMD) was
measured at only two main bone sites: the femoral neck
(FN) and the lumbar spine (LS). A high frequency of
osteoporosis (T-score ,–2.5) was verified in the FN (44.8%)
and LS (25.6%), whereas osteopenia (T-score ,–1.0 and .
–2.5) was also prevalent in the FN (41.4%) and LS (34.5%).
Considering all cases with reduced BMD (T-score ,–1.0),
the FN was more compromised (86.2%) than the LS
(60.1%). Of note, normal BMD in the LS was found in
37.9% of cases whereas normal BMD in the FN was
found in 13.8% of cases, suggesting a preferential de-
mineralization in mixed bone rather than in trabecular
bone. The high prevalence of osteopenia and osteoporosis
in the LS of these cases might suggest that in HPT/MEN1
patients the trabecular bone is less metabolically
‘‘protected’’ than in asymptomatic S-HPT patients (29–
31). The finding of severe osteopenia at the FN by 35 years
of age (T-score ,–2.0) in four of the nine cases (44%) of the
MEN1 subset with uncontrolled HPT suggest an early bone
disease in this MEN1-related HPT subset (29). One of the
illustrations in this study showed that there were 20
women who were younger than 50 years. Half of them
(10/20; 50%) had T-scores ,–2.0 for the FN and seven of
them had such scores for the LS (35%). The individual Z-
scores of the studied cases were not published, preventing
an analysis of the Z-scores for cases younger than 50 years,
as is presently recommended. Also, reduced BMD is
Table 1 - Classic comparisons of sporadic HPT and MEN1-related HPT.
Clinical characteristic MEN1-related HPT Sporadic HPT
Onset Earlier (20–30 years) Later (50–70 years)
Sex (M:F) 1:1 1:3
Germline MEN1 mutation Yes No
Pathology Multiglandular (hyperplasia) Uniglandular (adenoma)
Surgery Total or subtotal PTx Adenomectomy
Timectomy Yes No
Other associated tumors Yes No
Adverse effects of hypergastrinemia Yes No
Cure rate Low High (. 90%)
HPT recurrence rate after PTx High (,50%) Rare
HPT: primary hyperparathyroidism. MEN1: multiple endocrine neoplasia type 1. PTx: parathyroidectomy.
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100considered when the Z-score is ,–2.0 in individuals
younger than 50 years (32,33).
Although there were unknown numbers of untreated
and treated patients, BMD in the subset of patients with
controlled HPT was better than that in patients with
uncontrolled HPT (as measured by the Z-score), indicating
that previous BMD reports could be even more compro-
mised initially suspected. In addition, five patients could be
analyzed before and after successful subtotal parathyroi-
dectomy in this study. Although the number of patients was
limited, a marked increase in bone mass was noted at the
LS and FN over a mean follow-up period of 18 months,
suggesting a possible beneficial effect of early surgical
treatment for treating HPT/MEN1 cases, similar to that
observed in S-HPT cases (29,34,35).
Our first case series. The second paper addressing this
topic was published in 2008 and describes a large Brazilian
family with MEN1 and 50 clinically and/or genetically
affected members over six generations (36). BMD analysis
was performed in 20 HPT/MEN1 patients: 17 untreated cases
and three cases with uncontrolled HPT due to previously
unsuccessful parathyroid surgeries. In the 20 affected family
members, we examined cortical bone BMD in HPT/MEN1 for
the firstly approach (36).
Although the number of patients studied was limited, it
was possible to analyze data from both men and women
and a preliminary natural history of bone disease in MEN1
could be developed. Of the 20 cases, 75% and 60% of them
had osteoporosis (T ,–2.5) and osteopenia (T ,–1.0 and .
–2.5), respectively, in at least one of the three main bone
sites. Considering all cases with reduced BMD (T ,–1.0), the
most compromised bone site was the proximal one-third of
the distal radius (90%; 1/3DR), followed by the FN (65%),
and LS (60%) (36).
Osteoporosis was predominant in 1/3DR (55%), followed
by the LS (40%), and FN (20%). The degree of bone
demineralization was more severe in the cortical bone (T –
2.87¡0.32 for the 1/3DR), although L1–L4 (T –1.92¡0.39)
and the FN (T –1.48¡0.27) were also affected. Moreover,
cortical bone was the most compromised bone site in these
MEN1-related HPT cases, as it was the first to be affected and
presented with the highest prevalence of bone demineraliza-
tion and the worst BMD values (36). These findings are quite
similar to those that have been reported for S-HPT (30,31,35).
Data from our study (36) reinforce the findings of Burgess
et al. (29) by reporting a high frequency of reduced BMD of
the LS in the subset of MEN1-related HPT cases. In both
studies, patients presented with serum PTH levels that were
2- to 3-fold higher than the upper limit of the normal range,
as is frequently observed in asymptomatic S-HPT (34,35).
However, the relative protection of vertebral bone sites,
secondary to the anabolic effect of these PTH values on
trabecular bone, was not observed in the HPT/MEN1
subset, in contrast with data on S-HPT (29,31,36,37).
Norton case series. In a study on the long-term outcome
of PTx in 84 consecutive MEN1 cases with HPT associated
with gastrinoma (HPT/gastrinoma), Norton et al. (38)
reported a more severe form of HPT. In these cases, the
disease was characterized by a higher frequency of
nephrolithiasis at the time of diagnosis (62% vs. 40¡6%
from seven literature series), a higher frequency of recurrent
HPT (44% vs. 17% from 15 literature series, subtotal PTx),
and higher levels of PTH (2.4-fold vs. 1.67¡0.38 from eight
literature series). In addition, BMD studies were performed
in 56 of the 84 patients and bone demineralization was
observed in 47% of them (Z-scores were ,–2.0 in at least one
of the analyzed bone sites). These data led the authors to
suggest that a more virulent form of HPT presents in MEN1
cases with HPT/gastrinoma. However, the authors did not
indicate which bone sites had been examined (38). Of note,
Burgess et al. found no association between reduced bone
mass and a restricted number of cases with gastrinoma (29),
whereas no data on the BMD status of the subset of cases of
HPT/gastrinoma were available in our first case series (36).
Eller-Vainicher case series. This study was the first to
compare BMD data from a MEN1-related HPT series with
BMD data from S-HPT cases (39). Findings from 469 S-HPT
cases were compared with those of 64 HPT/MEN1 patients
(36 index cases and 28 affected relatives).
There was no significant difference between HPT/MEN1
index cases and their affected family members in terms of
clinical, biochemical, and BMD findings. However, HPT/
MEN1 patients had a tendency to be younger and have
lower serum levels of phosphate and PTH than patients
with S-HPT. Both HPT occurring before 50 years of age and
inappropriately normal PTH values were considered inde-
pendent, predisposing factors to MEN1-related HPT. Also,
the likelihood of association with the MEN1 syndrome was
13.5-fold greater when both factors were present (39).
A BMD analysis of LS and FN bone sites was conducted
in 432 patients (388 S-HPT and 44 HPT/MEN1 cases). In
both sites, bone mineral losses were more compromised in
the HPT/MEN1 subset than in the S-HPT subset (Z-scores:
LS, –1.33¡1.23 vs. –0.74¡1.40; FN, –1.13¡0.96 vs. –0.60
¡1.07). The prevalence of nephrolithiasis was similarly high
in both groups (57.8% vs. 55.2%) (39).
It was concluded that bone mineral disease is more severe
in cases with MEN1-related HPT than in cases with S-HPT.
These findings are in agreement with previous evidence
indicating the lack of relative protection of the vertebral
(trabecular) bone in HPT/MEN1 (10,29,36).
Kann case series. Recently, Kann et al. (40) studied BMD
in 23 patients with MEN1-related HPT using peripheral
quantitative computed tomography, and they confirmed the
previous findings of marked bone demineralization in
HPT/MEN1. Despite the limited number of patients and
the absence of statistical significance, it was suggested that
several other pathological conditions that potentially occur
in MEN1 could be responsible, in part, for the bone
demineralization observed in these cases. The conditions
cited as potentially influencers of the BMD values were
gonadotrophic and somatotrophic insufficiency, hypercor-
tisolism and a history of upper gastrointestinal surgery (40).
BMD after parathyroidectomy in HPT associated
with MEN1
The fifth study that examined BMD status in MEN1-
related HPT described short-term BMD changes that
occurred after PTx in 16 HPT/MEN1 cases. A significant
recovery in terms of BMD at the LS and FN, but not in the
1/3DR, was documented in 16 HPT/MEN1 patients at 15
months after PTx (41). These data contrast with the findings
of BMD recovery that were verified in cases with S-HPT, in
which a BMD gain was noticed in all three bone sites (35).
Several factors potentially influence or even determine the
differences in the patterns of BMD recovery in HPT/MEN1
compared with S-HPT: different surgical protocols (total
PTx in HPT/MEN1 vs. adenomectomy in S-HPT), the
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101amount of remnant parathyroid tissue, the degree of success
of parathyroid auto-implantations, and the lack of proper
PTH action for long periods in patients who undergo total
PTx.MostcasesreachedappropriatePTHlevels,asproduced
by the parathyroid implant, only 9 months after surgery (41).
Further long-term studies are needed to elucidate whether
a cortical bone BMD recovery after PTx would occur in HPT/
MEN1 cases. As the metabolic activity of cortical bone is
slower than that of trabecular bone (41), it would be expected
that a long-term BMD recovery at the 1/3DR may occur in
HPT/MEN1 patients under more prolonged PTH action.
Furthermore, we had the opportunity to first report the basal
and post-PTx values of bone formation and reabsorption
markers osteocalcin and CTX, respectively, in HPT/MEN1
(41). The levels of basal bone markers varied from mildly
high to normal, and a significant decrease was observed in
these cases after total PTx followed by parathyroid auto-
implantation in the non-dominant forearm (41).
Our second case series
Recently, we reported the first study to examine the early
and late outcomes of bone mineral and renal complications
in 36 patients with uncontrolled HPT from eight MEN1
families (10). These topics have been extensively studied in
sets of cases with S-HPT (30,34,35,42).
The peculiar clinical characteristics of these patients
provided the conditions required to study the outcome of
HPT cases associated with MEN1 (Table 2). Bone deminer-
alization was early, extensive, severe, and progressive in
these cases. The 1/3DR (cortical bone) was the preferentially
compromised bone site in younger patients and asympto-
matic cases (10).
In addition, the high prevalence of nephrolithiasis in cases
younger than 30 years and in most cases older than this age
suggested that a relatively short period of asymptomatic
HPT may be the rule for MEN1, in contrast to S-HPT cases
(Table 2) (10,35). However, as only 15 HPT/MEN1 cases
younger than 30 years and nine asymptomatic HPT/MEN1
cases were available to be studied (10,35), further long-
itudinal BMD data are needed in this set of cases.
In this study, progressive bone mineral loss could be
observed with aging and long-standing HPT disease. Thus,
in the older group (.50 years) bone demineralization
was significantly more frequent, extensive, and severe.
Furthermore, the older group had higher frequencies of
previous fractures and a progressive decrease in renal
function associated with a high frequency of nephrolithia-
sis-related co-morbidities (10) (Table 2).
Progressive demineralization of the cortical and trabecu-
lar bones was associated with the duration of HPT disease;
specifically, in cortical bone, this progression was also
observed in patients who had had HPT disease for more
than 10–20 years (Table 2). This bone demineralization
pattern differs from that reported for S-HPT, in which stable
bone disease occurred at these sites for the first 10 years of
disease followed by progressive demineralization of cortical
bone for up to 15 years (10,35).
DISCUSSION
We performed a meta-analysis of data on bone mineral
status and renal complications secondary to HPT associated
with MEN1.
Bone disease
Seven investigations have addressed this subject to date.
BMD in HPT/MEN1 cases was examined by most of these
studies, although different bone sites were analyzed and
different parameters were applied limiting an integrated
analysis (Table 3).
The LS, a site rich in trabecular bone, and the FN, a site
composed of mixed amounts of trabecular and cortical bone,
were analyzed in five of the seven studies by bone
densitometry (10,29,36,39,41). The 1/3DR, consisting mainly
of cortical bone, is the preferentially compromised bone site
in S-HPT (30,34,35,42); however, this site was examined in
only three of the latter five studies (10,36,41). One study did
not mention which bone sites were analyzed (38). A recent
study used peripheral quantitative computed tomography
instead of dual-energy X-ray absorptiometry to analyze the
bone mineral status (40) (Table 3).
Of note, different parameters were used to analyze BMD
in these studies. T-score values were preferentially used in
some studies, while Z-score values were utilized in others,
depending on the objectives and criteria recommended at
each time (Table 3) (29,41). At present, the criteria applied
for analyzing BMD were defined and officially adopted by
the International Society for Clinical Densitometry (ISCD) in
2008 and accepted by consensus on HPT in 2009 (32,33).
According to these criteria, BMD values should be mea-
sured by dual-energy X-ray absorptiometry at four major
bone sites: the lumbar spine (L1-L4), the FN, total hip (TH),
and the 1/3DR (32,33). The Z-score should be used for
patients younger than 50 years, whereas the T-score should
be used for patients older than 50 years. Z-score values ,–
2.0 or T-score values ,–1.0 indicate a reduced BMD, T-score
values between –1.0 and –2.5 indicate osteopenia and T-
scores ,–2.5 indicate osteoporosis (32,33). These new
criteria have been used in one BMD study of HPT/MEN1
cases so far (10).
The lack of available individual BMD data and the
superposition of patients who had been studied in an
earlier case sets were noticed in some of these studies,
limiting the possibility of a combined BMD analysis using
the ISCD criteria (32,33). A combination analysis using the
present ISCD criteria, excluding interposition of patients
from different studies, could be applied, in part, by using
BMD data from two studies (Table 4) (10,29).
ISCD criteria were applied to the findings obtained from
patients older than 50 years from the two latter studies;
BMD data from the LS and FN were reanalyzed for 24
patients and data from the TH and 1/3DR were reanalyzed
for 14 cases. BMD (T-score ,–1.0) was found to be reduced
in 79.1%, 83.3%, 100%, and 92.9% of cases at the LS, FN, TH,
and 1/3DR sites, respectively. Osteoporosis was more
prevalent than osteopenia in the LS (58.3% vs. 20.8%) and
in the 1/3DR (57.1% vs. 35.7%), but this condition was
equally prevalent in the FN (41.6%) and osteopenia was
dominant in TH (78.6% vs. 21.4%) (10,29). In this evaluation,
we included the older cases reported by Burgess et al.,
despite the presence of patients with uncontrolled (4/9
cases) and controlled HPT (5/9 cases). These findings
confirm recent data on outcomes in MEN1-related HPT
that indicate an increased frequency of age-related bone
demineralization in all bone sites in 15 untreated HPT/
MEN1 cases (Table 4) (10).
Presently, it is preferable that BMD data obtained from
younger patients be analyzed using the ISCD criteria. To
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MEN1 case series (10). An early onset of reduced BMD was
found in half (6/12) of patients below the age of 30 years.
Furthermore, in this study, 40% of patients younger than 50
years had reduced BMD at the 1/3DR compared with
23.8%, 25%, and 22.2% at the LS, FN, and TH, respectively.
Reduced BMD (Z-score ,–2.0) in at least one bone site was
noticed in 62% of all patients younger than 50 years (12/21),
confirming the presence of early bone demineralization
in MEN1-related HPT. In addition, this study confirms
previous BMD data obtained using T-score values and
indicates that bone demineralization in MEN1-related HPT
is most likely an early event (Table 4) (10,29). However,
further BMD data obtained from younger HPT/MEN1 cases
are necessary to clarify this issue.
In the subset of patients with S-HPT, the asymptomatic
form is more prevalent in developed countries. The
classical bone demineralization pattern of this condition
Table 2 - Early and late outcomes of renal and bone disease in MEN1-related HPT.
Characteristics of 36 MEN1-related HPT cases
N Symptomatic cases, predominantly (75%)
N Untreated cases, mainly (86.1%)
N All uncontrolled HPT
N Long-term disease (15.4¡12.8 years) (61%)
N Presence of young and old cases, including nine asymptomatic cases (25%)
Specific bone mineral profile (distinguishing characteristic from the profile of sporadic HPT)
Severe demineralization of cortical (1/3DR) and trabecular bone (LS)
Bone mineral outcome
Early stages Late stages
N Preferential demineralization in 1/3DR, which may be the only
compromised bone site N All bone sites are frequently demineralized and more severely
compromised
N Absence of vertebral bone protection N Vertebral and cortical bone are equally compromised, with a
predominance of osteoporosis
N Lower number of compromised bone sites in asymptomatic
cases and symptomatic cases with a shorter estimated period of
disease (less than 10 years)
N Higher number of compromised bone sites in symptomatic cases with
longer estimated period of disease (after 10 or 20 years)
N Bone disease may preceed renal disease N Higher frequency of fracture in cases older than 50years old (40%vs.4.8%)
Proximal one-third of the distal radius
Lower BMD in:
N cases with a history of HPT for more than 10 years and more than 20 years
N patients with HPT/gastrinoma
N patients with higher levels of calcium
Lumbar spine
Lower BMD in:
N patients who have had HPT for a longer time
Renal disease outcome
N Early onset of urolithiasis (86.2%, ,30 years)
N High frequency of therapeutic procedures to urolithiasis as surgery and lithotripsy (47.2%)
N Higher prevalence of different degrees of renal insufficiency in cases older than 50 years old (40%)
Data were obtained from Lourenc ¸o et al. (10). MEN1: multiple endocrine neoplasia type 1. HPT: primary hyperparathyroidism. LS: lumbar spine. 1/3DR:
proximal one-third of the distal radius. BMD: bone mineral density.
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bone (1-4,30,31,35). It was speculated that long-term
asymptomatic hypercalcemia could occur in HPT/MEN1
cases, similar to that reported in S-HPT (43). However, as
far as we know, no prospective study on this specific topic
has been performed to date. In this context, the BMD status
of asymptomatic HPT/MEN1 cases has been rarely studied
(10). So far, only nine asymptomatic HPT/MEN1 cases
have been analyzed in a cross-sectional study, although
early bone losses were documented in 44.4% of the cases
with a predominance of cortical bone demineralization.
Interestingly, eight of these patients (88.9%) were younger
than 30 years.
Renal disease in HPT associated with MEN1
A high frequency of early-onset nephrolithiasis was
documented in our patients before 30 years of age (86.2%),
suggesting the existence of a relatively short period of
asymptomatic hypercalcemia in this condition. Occasionally,
two asymptomatic cases became symptomatic soon after
the diagnosis of HPT (10). These findings supported the
hypothesis that patients with MEN1-related HPT have a
higher susceptibility to nephrolithiasis than S-HPT patients
(10,39,44,45).
Consistent with this view, Christopoulos et al. (45)
reported a high frequency of renal calculi in HPT/MEN1
patients before 30 years of age: 15 of the 17 younger patients
(82%) in the report presented with nephrolithiasis. Of note,
only three of our nine HPT/MEN1 patients with no renal
calculi were older than 30 years, reinforcing the early onset
of nephrolithiasis in MEN1-related HPT (10). These two
studies revealed a high frequency of kidney co-morbidities
secondary to nephrolithiasis (10,45). Taken together, these
two studies analyzed a total of 62 patients and 46 of them
(74.2%) had renal calculi. In 26 of these 46 cases (56.5%),
sessions of extra-corporeal shock-wave lithotripsy and/or
surgical procedures were needed to treat nephrolithiasis.
Three cases (6.5%) required unilateral nephrectomy because
of pyonephrosis and staghorn calculus presented as the first
renal clinical manifestation, acute obstructive urolithiasis
resulting in renal abscess and sepsis after only a few crisis of
renal calculi and chronic urolithiasis associated with recurrent
renal infections leading to complete loss of kidney function,
respectively (10,45). Different degrees of renal insufficiency
were reported in seven of 29 HPT/MEN1 cases (19.4%). In
two patients older than 47 years of age, creatinine clearance
rates less than 44 ml/min/1.73 m
2 were reported (10).
HPT associated with MEN1 and gastrinoma
Norton et al. (38) reviewed seven series of MEN1-related
HPT and the frequency of nephrolithiasis in this group was
40¡6%. It was suggested that MEN1 patients with HPT/
gastrinoma had a higher susceptibility to the development
of nephrolithiasis (62%) and a higher frequency of reduced
BMD (46%). However, other studies revealed similar
frequencies for nephrolithiasis (57.8–75%), independent of
the presence of gastrinoma (10,39,45). In one of these series,
a higher frequency of nephrolithiasis, although not statisti-
cally significant, was found in MEN1-related HPT cases
with gastrinoma than in MEN1-related HPT cases without
Table 3 - The methods used in the seven studies that examined bone mineral status in MEN1-related HPT.
Literature/Method
Number
of patients Bone sites Criteria used in BMD analysis
Burgess et al. (29)/DXA 29 LS
FN
T-scores*:
Osteopenia, ,21.0
Severe osteopenia, ,22.0
Osteoporosis, ,22.5
Z-score*:
.–1.0; ,–1.0; ,–2.0
Lourenc ¸o et al. (36)/DXA 20 LS
FN
1/3 DR
T-scores*:
Osteopenia, ,21.0
Osteoporosis, ,22.5
Norton et al. (38) 56 Not available Any Z score #–2.0
Eller-Vainicher et al. (39)/DXA 44 LS
FN
Z score #–2.0
Coutinho et al. (41)/DXA 16 LS
FN
TH
1/3 DR
UDR
Mean values of:
g/cm
2, T- and Z-scores before/after PTx
Lourenc ¸o et al. (10)/DXA 36 LS
FN
TH
1/3 DR
T-scores**:
Reduced BMD, ,–1.0
Osteopenia, –1.0 to –2.5
Osteoporosis, ,–2.5
Z score***:
Reduced BMD, #–2.0
Khan et al. (40)/pqCT (g/cm
3) 23 Forearm
Trabecular BMD/
total BMD
Z-score:
.–1: normal
–1 to –2: low
,–2: reduced
BMD: bone mineral density. MEN1: multiple endocrine neoplasia type 1. HPT: primary hyperparathyroidism. DXA: dual-energy X-ray absorptiometry.
pqCT: peripheral quantitative computed tomography. LS: lumbar spine. FN: femoral neck. 1/3DR: proximal one-third of the distal radius. TH: total hip.
UDR: ultra distal radius. T-scores: difference from the mean BMD value in a healthy young reference population, in SD units. Z-scores: age-matched
comparison, in SD units. *: independent of age. PTx: parathyroidectomy. **: performed in patients older than 50 years of age. ***: performed in patients
younger than 50 years of age.
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104gastrinoma (93.3% vs. 71.4%) (10). Bias might have occurred
with these data because of the limited number of patients
available for comparisons. Of note, the onset of gastrinomas
in patients with MEN1 usually occurs between 30–50 years
of age, when most patients have already developed renal
calculi (10,45).
In the same study, using ISCD criteria, MEN1 cases with
HPT/ gastrinoma had higher frequencies of reduced BMD
independent of the bone site than HPT/MEN1 cases without
gastrinoma (86.7% vs. 52.4%, p,0.03) (10). Demineralization
at the 1/3DR in HPT/gastrinoma cases was significantly
more severe than in HPT-only MEN1 cases (p,0.013) (10). In
addition, there was a tendency for higher PTH and calcium
levels in our HPT/gastrinoma cases, reinforcing data
reported by Norton et al. (10,38). When individual data
from our second case series were reviewed and the criteria
used by Norton et al. were applied (Z ,–2.0, independent of
the bone site), 66.7% of the cases presented reduced BMD
independent of the presence of gastrinoma. However, no
appropriate comparisons could be performed between these
two studies, as BMD data for the specific bone sites were not
available for the cases reported by Norton et al. (38) and
because we had a limited number of gastrinoma/MEN1
cases (10).
Biochemical data on HPT associated with MEN1
Several studies have reported mild biochemical disease
associated with MEN1-related HPT, with modestly elevated
levels of calcium and a predominance of PTH values that
are 2- to 3-fold above the upper limit of the normal range.
Two earlier studies demonstrated a direct correlation
between age and calcium/PTH values in a subset of
patients with MEN1-related HPT, which is probably
associated with the progressive development of parathyroid
hyperplasia and the asynchronous onset of HPT disease in
the different parathyroid glands (46,47). A tendency toward
increasing PTH levels was also observed in older patients
after long periods of HPT disease (10).
Furthermore, Eller-Vainicher et al. (39) reported a direct
association between increasing PTH/calcium levels and
aging. These authors also reported an association between
inappropriately normal serum PTH values and age below 50
years with presence of HPT/MEN1. Thus, fifteen of the 40
HPT/MEN1 patients younger than 50 years (37.5%) had
inappropriately normal PTH levels. Additionally, cases
younger than 50 years and presenting inappropriately
normal PTH levels had 13.5 fold higher likelihood of
association with MEN1 syndrome than patients with 50
years old or more and presenting high serum levels of PTH.
(39).
Combining data from Burgess et al. ’s study and our
own, the prevalence of inappropriately normal PTH levels
was 9.2% (6/65), independent of age (10,29). However, the
real prevalence could be even higher once controlled and
uncontrolled HPT cases from the study by Burgess et al.
(29) are included in the present evaluation. One of the six
Table 4 - Comparative analysis of BMD findings using the ISCD (2009) criteria (32,33).
BMD pattern in MEN1-related HPT LS (n) FN (n) TH (n) 1/3DR (n)
Group younger than 50 years of age with reduced BMD (Z , -2.0)
Burgess et al. (29) - - - -
Lourenc ¸o et al. (10) 23.8 (5/21) 25 (5/20) 22.2 (4/18) 40 (8/20)
Total 23.8 (5/21) 25 (5/20) 22.2 (4/18) 40 (8/20)
Group older than 50 years of age with reduced BMD (T , -1.0)
Burgess et al. (29) 77.7 (7/9) 100 (9/9) - -
Lourenc ¸o et al. (10) 80 (12/15) 73.3 (11/15) 100 (14/14) 92.9 (13/14)
Total 79.1 (19/24) 83.3 (20/24) 100 (14/14) 92.9 (13/14)
Group older than 50 years of age with osteoporosis (T , -2.5)
Burgess et al. (29) 44.4 (4/9) 66.6 (6/9) - -
Lourenc ¸o et al. (10) 67.7 (10/15) 26.7 (4/15) 21.4 (3/14) 57.1 (8/14)
Total 58.3 (14/24) 41.6 (10/24) 21.4 (3/14) 57.1 (8/14)
Group older than 50 years of age with osteopenia (-2.5 , T , -1.0)
Burgess et al. (29) 33.3 (3/9) 33.3 (3/9) - -
Lourenc ¸o et al. (10) 13.3 (2/15) 46.7 (7/15) 78.6 (11/14) 35.7 (5/14)
Total 20.8 (5/24) 41.6 (10/24) 78.6 (11/14) 35.7 (5/14)
Reduced BMD: Z , -2.0 in younger patients (,50 years) and T , -1 in older patients (.50 years)
Burgess et al. (29) 77.7 (7/9)* 100 (9/9)* - -
Lourenc ¸o et al. (10) 47.2 (17/36) 45.7 (16/35) 56.2 (18/32) 61.8 (21/34)
Total 53.3 (24/45) 56.8 (25/44) 56.3 (18/32) 61.8 (21/34)
Reduced BMD (Z , -2.0), independent of age
Burgess et al. (29) 20.7 (6/29) 27.6 (8/29) - -
Lourenc ¸o et al. (10) 36.1 (13/36) 20 (7/35) 18.8 (6/32) 47.1 (16/34)
Total 29.2 (19/65) 23.4 (15/64) 18.8 (6/32) 47.1 (16/34)
BMD: bone mineral density. ISCD: International Society for Clinical Densitometry. MEN1: multiple endocrine neoplasia type 1. HPT: primary
hyperparathyroidism. LS: lumbar spine. FN: femoral neck. TH: total hip. 1/3DR: proximal one-third of the distal radius. T-scores: difference from the mean
BMD value in a healthy young reference population, in SD units. Z-scores: age-matched comparison, in SD units. *: only patients older than 50 years were
included.
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105cases in our series had asymptomatic HPT and another
had recurrent HPT (10). It is possible that HPT/MEN1
cases in these two studies (10,29) were diagnosed later
than in the study by Eller-Vainicher et al. (39). In addition,
the laboratory diagnosis of HPT in the Eller-Vainicher
study may have been more rigorously performed, as
serum PTH levels were considered after adjusting for age
and sex (39).
Biochemical data and BMD
Correlations between biochemical and BMD data in HPT/
MEN1 are contrasting. Burgess et al. reported an inverse
correlation between PTH levels and LS and FN BMD
findings, but not with regard to calcium levels. Conversely,
no correlation between PTH levels with BMD values were
observed in other studies (10,39). Of note, an inverse
correlation between calcium levels and 1/3 DR BMD values
was reported (10).
Other conditions associated with MEN1 and BMD
Recently, Kaan et al. (40) used peripheral quantitative
computed tomography to analyze BMD and reported a
higher prevalence of bone demineralization in HPT/MEN1
cases (48% in trabecular BMD and 60% in total BMD) than
in the normal population (15%). However, most of these
cases had been previously submitted to PTx and, thus, a
postsurgical BMD gain had probably occurred. Thus, the
real prevalence of bone demineralization in this group of
patients could be even higher. Despite the limited number
of cases and the lack of statistical significance of the
findings, it was suggested that other associated factors
might influence the BMD status of these cases (40). This
conclusion was based on the presence of five cases (22.7%)
with hypopituitarism secondary to gonadotrophic and/or
somatotrophic insufficiency, three cases with hypercortiso-
lism (13.6%), and 12 cases (52%) with previous surgeries to
the upper gastrointestinal tract (40). Other studies that
examined this subject produced different results. Burgess
et al. (29) found no association between hypogonadism
secondary to prolactinoma or menopausal status and
reduced BMD. Eller-Vainicher reported 10 cases with
hyperprolactinemia but without hypogonadism and no
cases with hypopituitarism (39). Also, we recently reported
no difference in BMD status between six postmenopausal
and 12 premenopausal women, as well as between 10 cases
with and 26 cases without prolactinoma (10). In this latter
study, the HPT/MEN1 cases with prolactinoma had been
successfully treated with bromoergocriptine or a similar
agent and a potential BMD recovery might have interfered
with the statistical results. It is most likely that prolacti-
noma and menopause occur much more frequently in
MEN1 than hypopituitarism secondary to pituitary macro-
adenoma or hypercortisolism, in contrast with data from
Kaan et al. (40). However, large studies are needed to
clarify this issue.
The prevalence of pituitary adenoma in familial MEN1 was
evaluated by Verges et al. and found to be 34% (14).
Prolactinoma was the most frequent pituitary tumor (68%),
and macroadenoma was highly prevalent in this sample (85%)
(14). Based on these data, we could estimate that one-fifth and
one-third of MEN1 patients, respectively, might potentially
develop prolactinomas and macroadenomas. However, the
actual prevalence of hypopituitarism in MEN1 is currently
unknown. Somatotropinomas are relatively rare in MEN1
(14,15) and should be differentiated from familial and isolated
acromegaly/gigantism caused by other gene mutations, such
as AIP (13,16-19). Hypercortisolism occurs infrequently in
MEN1 (up to 7% of cases) (14), although several studies
involving large series reported no case with hypercortisolism
in MEN1 (10,36,39,41).
Of note, Kaan et al. analyzed the potential impact of
previous gastrointestinal surgeries on BMD and found no
significant correlations (40). Although several factors may
potentially worsen bone mineral status in MEN1, a satisfac-
tory BMD recovery could be provided to patients if MEN1-
related conditions are promptly diagnosed and treated.
Genetics and MEN1
BMD studies on HPT/MEN1 have also examined
connections with the genetic status of these cases. Burgess
et al. studied 29 affected women from a large MEN1 family
harboring a known germline MEN1 mutation (29).
However, genotyping could not be performed on all of the
studied cases. Thus, the possibility of phenocopies, which
may occur in up to 5% of MEN1 families (20,48), could not
be fully excluded from these cases.
Eller-Vainicher studied a series of 64 affected patients
from 36 unrelated MEN1 families (39). A germline MEN1
mutation was found in 31 index cases but not in the
remaining three index cases that were included in this
sample of familial MEN1 genealogies because they had
typical MEN1-affected relatives.
In three other studies, all affected cases belonging to
MEN1 families harboring novel or previously reported
germline MEN1 mutations and all index cases, as well as
affected family members, were genetically documented
(10,23,24,36,41).
Norton et al. reported a familial history of MEN1 in 68 of
the 81 (81%) studied cases (38). A germline MEN1 mutation
was found in 61 cases (75.3%), nine cases had no MEN1
mutation and the genetic status of 14 other cases was
unknown. Kaan found a germline MEN1 mutation in all of
the cases studied, except one (22/23; 95.7%) (40).
It is worth noting that an appropriate selection of
genetically characterized MEN1 cases is needed, as the
pathogeneses of sporadic MEN1 and of familial MEN1 cases
that do not harbor a germline MEN1 mutation are different.
Prospective studies
Despite the absence of prospective studies focusing on the
early and late outcomes of renal and bone mineral
complications in the MEN1-related HPT subset, an inte-
grated analysis of the published data may contribute to a
better understanding of several critical topics and allow us
to add to the list of differences between HPT/MEN1 and S-
HPT (Table 5).
Treatment of MEN1
Themain challenge associatedwith theMEN1-relatedHPT
subset is improving the treatment options for this condition,
as the recurrence rate of HPT may be as high as 50% in the
period of 5–10 years after PTx (7,8,29,49). Also, the increasing
survival rate of MEN1 patients may result in an increasing
number of MEN1 patients with post-PTx hypoparathyroid-
ism. Calcimimetic drugs are a potential tool that could be
used to modify this outcome. HPT was controlled with 30
mg/daycinacalcetover a 12-monthperiodina MEN1patient
who refused a second PTx because of local recurrence, and a
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106BMD recovery at the LS (4.7%) and TH (17.8%) was seen 1
year after treatment (50). Recently, Moyes et al. documented
metabolic PTH/calcium control 10–35 months after cinacal-
cet therapy in seven MEN1-related HPT cases (51). Despite
the absence of new episodes of nephrolithiasis during the
follow-up period, there was no significant BMD gain in five
of the seven cases studied (51).
The current evidence shows that HPT/MEN1 is asso-
ciated with a high prevalence of HPT-related comorbidities.
Severe and frequent bone and renal diseases have been
documented in these cases, mostly occurring in earlier but
also at later stages of HPT. A better understanding of the
natural history of HPT/MEN1 disease; further improve-
ments in surgical techniques; and the development of
secure, efficient, and well-tolerated calcimimetic drugs
may enable more appropriate therapies to be developed
for this subset of patients. It is hoped that in the near future
therapeutic improvements may potentially prevent the
development of bone and renal complications in HPT/
MEN1 cases, correct metabolic disturbances, and avoid
postsurgical hypoparathyroidism, as well as provide better
management of recurrences. At present, adequate surveil-
lance of bone, renal, and other co-morbidities in MEN1-
related HPT should be performed, thereby contributing to
an improved determination of the optimal timing for
subtotal or total parathyroid surgery.
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